Compare Crispr Therapeutics AG (CRSP) vs Fortinet Inc (FTNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Fortinet Inc — how do they compare? Crispr Therapeutics AG trades at $54.14 (market cap $5.23B), while Fortinet Inc trades at $161 (market cap $118.78B). The key difference: Fortinet Inc is far larger — about 22.7× Crispr Therapeutics AG's market cap, and Fortinet Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | FTNT | |
|---|---|---|
Market Cap | $5.23B | $118.78B |
Sector | Health | Technology |
52-Week High | $76.78 | $168.29 |
52-Week Low | $44.34 | $75.23 |
Enterprise Value | $3.65B | $115.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Fortinet (FTNT) trades at $161.21, down 1.83% over 24 hours, with a bullish technical signal from moving averages and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $0.90 versus $0.746 expected, driven by robust demand for cybersecurity solutions amid AI-driven security needs. Revenue growth has accelerated from $4.4B in 2022 to $6.8B in 2025, with net income margins above 28%, though valuation ratios like P/E of 57.2 indicate premium pricing.
The outlook remains positive given consistent earnings beats and analyst consensus price target of $174.50, offering ~8% upside. Key risks include high valuation multiples, competitive pressures in cybersecurity, and negative net cash flow trends. Institutional sentiment is mixed with 42.65% buy ratings, but growth in AI security and SASE firewall adoption supports long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →
